Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free MPT Stock Alerts

Medical Properties Trust (MPT) Financials

Medical Properties Trust logo
$3.59 -0.05 (-1.37%)
As of 10:34 AM Eastern
Compare
Annual Income Statements for Medical Properties Trust

Annual Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 140 225 290 1,017 375 431 656 903 -556 -2,410 -277
Consolidated Net Income / (Loss)		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Net Income / (Loss) Continuing Operations		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Total Pre-Tax Income 		140 219 294 1,019 374 463 731 960 -687 -2,364 -237
Total Revenue		 442 541 705 785 616 921 1,177 1,543 461 578 462
Net Interest Income / (Expense)		 0.00 0.00 0.00 162 -238 -329 -367 0.00 -411 -418 -510
Total Interest Income		 0.00 0.00 0.00 162 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 0.00 238 329 367 0.00 411 418 510
Long-Term Debt Interest Expense		 - - - - 238 329 367 - 411 418 510
Total Non-Interest Income		 442 541 705 622 854 1,249 1,545 1,543 872 996 972
Other Service Charges		 112 108 129 - 150 142 169 166 69 49 44
Other Non-Interest Income		 330 433 576 622 704 1,107 1,376 1,377 803 947 928
Total Non-Interest Expense		 179 359 396 495 294 421 506 898 791 609 432
Other Operating Expenses		 44 211 241 314 120 157 185 520 187 161 167
Depreciation Expense		 70 94 125 133 152 264 321 333 603 448 265
Nonoperating Income / (Expense), net		 -123 37 -15 729 51 -36 60 315 -357 -2,333 -267
Income Tax Expense		 - -6.83 2.68 0.93 -2.62 31 74 56 -131 44 39
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.33 0.89 1.45 1.79 1.72 0.82 0.92 1.22 0.38 1.98 1.11
Basic Earnings per Share		 $0.64 $0.86 $0.82 $2.77 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Weighted Average Basic Shares Outstanding		 218.00M 260.41M 349.90M 365.36M 427.08M 529.24M 588.82M 598.63M 598.52M 600.25M 600.89M
Diluted Earnings per Share		 $0.63 $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Weighted Average Diluted Shares Outstanding		 218.30M 261.07M 350.44M 366.27M 428.30M 530.46M 590.14M 598.84M 598.52M 600.25M 600.89M
Weighted Average Basic & Diluted Shares Outstanding		 218.10M 261.70M 353.40M 367M 520.93M 580M 599.90M 598.30M 599.10M 600.60M 597.70M
Cash Dividends to Common per Share		 $0.87 $0.90 $0.95 $0.99 $1.01 $1.07 $1.11 $1.15 $1.17 $0.38 $0.32

Quarterly Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -664 -876 -321 -801 -413 -118 -98 -78 17 33 -2.60
Consolidated Net Income / (Loss)		 -664 -875 -320 -801 -412 -118 -98 -77 18 33 -2.29
Net Income / (Loss) Continuing Operations		 -664 -875 -320 -801 -412 -118 -98 -77 18 33 -2.29
Total Pre-Tax Income 		-660 -864 -305 -792 -403 -109 -88 -67 26 0.29 7.79
Total Revenue		 -427 163 165 120 130 108 111 105 138 119 124
Net Interest Income / (Expense)		 -337 -109 -101 -106 -101 -116 -130 -132 -132 -133 -135
Total Interest Income		 -32 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Interest Expense		 304 109 101 106 101 116 130 132 132 133 135
Long-Term Debt Interest Expense		 - 109 101 106 101 116 130 132 132 133 135
Total Non-Interest Income		 -90 271 267 226 232 224 240 238 270 252 259
Other Service Charges		 - 11 17 9.71 11 8.58 13 10 12 10 12
Other Non-Interest Income		 -69 260 250 216 220 215 227 227 258 242 247
Total Non-Interest Expense		 -91 114 145 246 103 114 104 114 101 112 115
Other Operating Expenses		 -169 38 43 42 38 49 37 47 34 42 46
Depreciation Expense		 77 76 102 205 65 65 67 67 67 70 69
Nonoperating Income / (Expense), net		 -324 -913 -325 -665 -430 -103 -95 -58 -11 -6.59 -0.81
Income Tax Expense		 3.98 11 15 9.03 9.56 9.44 9.80 11 8.51 -33 10
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.36 0.25 0.98 0.23 0.53 0.26 0.29 0.28 0.28 0.28 0.31
Basic Earnings per Share		 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05 ($0.01)
Weighted Average Basic Shares Outstanding		 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M 597.96M
Diluted Earnings per Share		 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05 ($0.01)
Weighted Average Diluted Shares Outstanding		 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M 597.96M
Weighted Average Basic & Diluted Shares Outstanding		 599.10M 600.10M 600.20M 600.40M 600.60M 600.80M 601.10M 601.50M 597.70M 598.10M 597.20M
Cash Dividends to Common per Share		 - $0.00 $0.30 $0.08 - $0.08 $0.08 $0.08 - $0.09 $0.09

Annual Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 62 -110 70 667 652 -928 -99 -207 3.02 84 194
Net Cash From Operating Activities		 207 264 362 449 494 618 812 739 506 245 231
Net Cash From Continuing Operating Activities		 207 264 362 449 499 618 812 739 506 245 231
Net Income / (Loss) Continuing Operations		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Consolidated Net Income / (Loss)		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Depreciation Expense		 72 98 132 141 157 276 334 346 616 454 273
Amortization Expense		 6.09 7.61 6.52 7.36 8.88 13 17 17 16 17 26
Non-Cash Adjustments to Reconcile Net Income		 -26 -76 -44 906 -95 -101 -209 -441 555 2,193 173
Changes in Operating Assets and Liabilities, net		 15 9.13 -24 -34 53 -2.60 13 -87 -125 -9.85 34
Net Cash From Investing Activities		 -1,946 -927 -2,362 564 -4,884 -2,947 -3,858 396 518 1,318 -265
Net Cash From Continuing Investing Activities		 -1,946 -927 -2,362 564 -4,884 -2,947 -3,858 396 518 1,318 -265
Purchase of Property, Leasehold Improvements and Equipment		 -146 -171 -74 - -84 -68 -68 -109 -114 -80 -80
Purchase of Investment Securities		 -2,590 -1,911 -2,361 - -4,913 -4,348 -5,698 -1,748 -780 -682 -422
Sale and/or Maturity of Investments		 791 1,156 73 4,181 113 1,470 1,908 2,253 1,412 2,080 237
Net Cash From Financing Activities		 1,801 553 2,070 -346 5,042 1,401 2,948 -1,343 -1,020 -1,479 228
Net Cash From Continuing Financing Activities		 1,801 553 2,070 -252 5,042 1,812 2,948 -1,343 -1,020 -1,479 228
Net Change in Deposits		 -11 15 28 21 -12 22 18 -5.02 10 2.24 -3.20
Issuance of Debt		 1,190 1,000 2,906 760 2,983 2,379 3,968 129 568 -327 2,513
Issuance of Common Equity		 817 1,174 548 188 2,533 411 1,051 0.00 0.00 0.00 0.00
Repayment of Debt		 -0.28 -1,385 -1,038 -812 0.00 -800 -1,391 -666 -988 -702 -2,011
Repurchase of Common Equity		 - - - - - 0.00 0.00 -18 0.00 0.00 -23
Payment of Dividends		 -183 -218 -327 364 -412 -568 -643 -699 -615 -321 -193
Other Financing Activities, Net		 -13 -32 -46 -3.61 -50 369 -54 -84 5.18 -132 -54
Cash Interest Paid		 214 278 150 222 211 310 326 354 406 420 458

Quarterly Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -97 -23 384 - 69 675 -351 -222 92 -114 -28
Net Cash From Operating Activities		 135 74 35 - 77 0.77 103 37 89 -14 62
Net Cash From Continuing Operating Activities		 135 28 35 - 204 50 149 77 -45 21 97
Net Income / (Loss) Continuing Operations		 -664 -875 -320 - -412 -236 -196 -155 311 33 -2.29
Consolidated Net Income / (Loss)		 -664 -875 -320 - -412 -236 -196 -155 311 33 -2.29
Depreciation Expense		 80 77 104 - 66 131 136 139 -133 73 74
Amortization Expense		 3.80 3.70 3.79 - 5.08 12 13 14 -12 6.98 6.57
Non-Cash Adjustments to Reconcile Net Income		 727 834 308 - 519 205 156 119 -306 -31 19
Changes in Operating Assets and Liabilities, net		 -12 -12 -61 - 26 -61 40 -40 95 -61 0.62
Net Cash From Investing Activities		 170 -119 1,202 - 92 -179 -145 -190 249 -77 -82
Net Cash From Continuing Investing Activities		 170 -119 1,202 - 92 -83 -125 -116 59 -77 -82
Purchase of Property, Leasehold Improvements and Equipment		 -34 -30 -15 - -16 - - - - -13 -7.47
Purchase of Investment Securities		 -106 -222 -289 - 16 -122 -187 -229 117 -131 -90
Sale and/or Maturity of Investments		 310 133 1,507 - 92 40 62 112 23 67 15
Net Cash From Financing Activities		 -403 22 -854 - -100 853 -310 -69 -246 -23 -8.30
Net Cash From Continuing Financing Activities		 -403 22 -854 - -100 336 -100 -97 -4.71 -23 -8.30
Net Change in Deposits		 2.39 6.23 2.28 - 2.96 6.49 -2.55 1.01 -8.15 4.41 -0.50
Issuance of Debt		 141 0.00 693 - -12 5,026 - - -2,513 30 55
Payment of Dividends		 -91 -93 -90 - -48 -96 -97 -97 96 -55 -54
Other Financing Activities, Net		 -0.98 -0.28 -78 - -3.76 -95 -0.91 -1.47 -51 -2.29 -2.43
Effect of Exchange Rate Changes		 - - - - - - - - - -1.79 -0.34
Cash Interest Paid		 84 132 123 - 71 236 205 346 -328 174 105

Annual Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5,609 6,419 9,020 8,844 14,467 16,829 20,520 19,658 18,305 14,295 15,002
Cash and Due from Banks		 196 83 171 821 1,462 550 459 236 250 332 541
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 2,992 3,968 5,307 4,781 7,312 10,750 - 12,468 - 10,456 12,206
Mortgage Servicing Rights		 758 1,060 1,778 1,213 1,275 248 213 364 309 120 124
Intangible Assets		 232 264 394 352 557 1,194 - 1,209 - 603 -1,663
Other Assets		 1,433 1,043 1,369 1,156 2,934 2,964 3,239 5,381 2,663 4,005 2,073
Total Liabilities & Shareholders' Equity		 5,609 6,419 9,020 8,844 14,467 16,829 20,520 19,658 18,305 14,295 15,002
Total Liabilities		 3,502 3,165 5,185 4,283 7,439 9,485 12,074 11,064 10,671 9,461 10,395
Other Short-Term Payables		 137 208 - 204 - 439 - 621 - - 549
Long-Term Debt		 3,323 2,909 4,899 4,037 7,024 8,865 11,283 10,268 10,064 8,848 9,698
Other Long-Term Liabilities		 29 20 229 41 554 181 791 174 607 613 148
Total Equity & Noncontrolling Interests		 2,107 3,253 3,835 4,561 7,028 7,344 8,446 8,594 7,634 4,834 4,607
Total Preferred & Common Equity		 2,102 3,248 3,821 4,547 7,028 7,339 8,440 8,593 7,632 4,833 4,606
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,102 3,248 3,821 4,547 14,119 7,339 8,440 8,593 7,632 4,833 4,606
Common Stock		 2,594 3,776 4,333 4,443 14,029 7,462 8,565 8,536 8,561 8,586 8,574
Retained Earnings		 -419 -434 -486 163 83 -71 -88 116 -972 -3,659 -4,136
Accumulated Other Comprehensive Income / (Loss)		 -73 -93 -26 -58 -63 -51 -37 -59 43 -94 168
Noncontrolling Interest		 5.00 4.85 15 14 0.11 5.33 5.48 1.57 2.27 1.05 1.05

Quarterly Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 8,890 19,204 19,005 17,301 16,195 15,236 14,854 15,150 14,924 14,763 14,748
Cash and Due from Banks		 707 324 340 224 607 276 673 510 397 425 397
Loans and Leases, Net of Allowance		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 - - - - 11,949 11,654 - 11,892 - 10,396 12,147
Mortgage Servicing Rights		 - 299 302 310 399 298 121 124 128 124 131
Intangible Assets		 541 11,882 11,727 11,401 -1,418 -1,424 10,009 -1,600 10,115 - -1,747
Other Assets		 - 6,699 6,635 5,366 4,658 4,432 4,050 2,541 4,284 3,817 2,134
Total Liabilities & Shareholders' Equity		 8,890 19,204 19,005 17,301 16,195 15,236 14,854 15,150 14,924 14,763 14,748
Total Liabilities		 6,380 10,890 10,719 10,597 10,002 9,795 10,092 10,317 10,263 10,217 10,248
Other Short-Term Payables		 - 445 376 303 447 418 451 495 476 - 430
Long-Term Debt		 972 10,238 10,157 10,099 9,369 9,216 9,465 9,649 9,616 9,663 9,705
Other Long-Term Liabilities		 - 207 186 195 186 161 175 173 171 554 113
Total Equity & Noncontrolling Interests		 2,509 8,315 8,285 6,704 6,193 5,441 4,762 4,834 4,661 4,546 4,500
Total Preferred & Common Equity		 2,498 8,314 8,285 6,702 6,190 5,439 4,761 4,833 4,660 4,545 4,499
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,498 8,314 8,285 6,702 6,190 5,439 4,761 4,833 4,660 4,545 4,499
Common Stock		 3,492 8,548 8,559 8,568 8,572 8,579 8,591 8,599 8,604 8,578 8,578
Retained Earnings		 3,946 -241 -215 -1,847 -2,348 -3,198 -3,825 -3,972 -4,098 -4,157 -4,214
Accumulated Other Comprehensive Income / (Loss)		 -452 6.68 -60 -19 -34 57 -4.82 206 155 124 135
Noncontrolling Interest		 11 0.90 0.89 2.27 2.90 2.54 1.05 1.05 1.05 1.05 1.05

Annual Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 237,837,152.00 320,247,632.00 364,156,080.00 364,941,199.00 517,440,399.00 535,996,738.00 596,300,000.00 598,000,000.00 599,000,000.00 600,400,000.00 601,500,000.00
DEI Adjusted Shares Outstanding		 237,837,152.00 320,247,632.00 364,156,080.00 364,941,199.00 517,440,399.00 535,996,738.00 596,300,000.00 598,000,000.00 599,000,000.00 600,400,000.00 601,500,000.00
DEI Earnings Per Adjusted Shares Outstanding		 0.59 0.71 0.80 2.79 0.73 0.81 1.10 1.51 -0.93 -4.01 -0.46
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.64 $0.86 $0.82 $2.77 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 218.00M 260.41M 349.90M 365.36M 427.08M 529.24M 588.82M 598.63M 598.52M 600.25M 600.89M
Adjusted Diluted Earnings per Share		 $0.63 $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 218.30M 261.07M 350.44M 366.27M 428.30M 530.46M 590.14M 598.84M 598.52M 600.25M 600.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.87 $0.00 $1.11 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 237.85M 320.93M 364.69M 381.08M 520.93M 580M 599.90M 598.30M 599.10M 600.60M 597.70M
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 599,000,000.00 599,100,000.00 600,100,000.00 600,200,000.00 600,400,000.00 600,600,000.00 600,800,000.00 600,800,000.00 601,500,000.00 597,700,000.00 598,100,000.00
DEI Adjusted Shares Outstanding		 599,000,000.00 599,100,000.00 600,100,000.00 600,200,000.00 600,400,000.00 600,600,000.00 600,800,000.00 600,800,000.00 601,500,000.00 597,700,000.00 598,100,000.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.11 -1.46 -0.53 -1.33 -0.69 -0.20 -0.16 -0.13 0.03 0.06 0.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -103.35% -53.56% -51.06% -40.17% 2,904.12% -33.59% -32.99% -12.09% - 9.94% 12.08%
EBITDA Growth		 -202.68% -38.62% -29.25% -51.87% 139.10% 5.50% 22.90% 84.80% - -36.32% 738.39%
EBIT Growth		 -314.50% -59.22% 110.38% -263.81% 108.09% -111.29% -65.46% 93.23% - 224.51% 25.05%
NOPAT Growth		 -308.02% -68.39% 110.38% -224.54% 108.09% -111.29% -65.46% 93.23% - 20,762.56% -152.48%
Net Income Growth		 -373.27% -2,750.25% -653.33% -785.17% 37.86% 86.52% 69.32% 90.33% - 128.05% 97.67%
EPS Growth		 -358.33% -3,020.00% -671.43% -805.26% 38.18% 86.30% 70.37% 90.30% - 125.00% 93.75%
Operating Cash Flow Growth		 -25.22% -45.19% -53.93% 0.00% -43.37% -98.97% 193.53% 0.00% - -1,956.64% 21.57%
Free Cash Flow Firm Growth		 -4.97% 699.61% 844.25% 6,084.82% 333.94% 21.74% -63.91% -89.90% - -68.21% -74.59%
Invested Capital Growth		 -6.17% -11.01% -16.12% -20.53% -22.69% -15.33% -6.94% -2.59% - -0.13% -1.92%
Revenue Q/Q Growth		 -107.84% 1,137.58% 1.54% -27.58% 267.54% -75.43% 2.46% -4.99% - -13.89% 4.45%
EBITDA Q/Q Growth		 -255.40% 151.56% -1.73% -38.87% 16.72% 39.11% 14.48% -8.09% - 179.81% 1.81%
EBIT Q/Q Growth		 -533.01% 114.57% -59.29% -737.74% 121.40% -120.33% 224.51% -225.03% - -81.25% 25.05%
NOPAT Q/Q Growth		 -429.19% 114.57% -59.29% -737.74% 121.40% -120.33% 224.51% -225.03% - 3,131.20% -100.32%
Net Income Q/Q Growth		 -667.68% -31.92% 63.48% -150.56% 48.52% 71.38% 16.90% 21.02% - 88.14% -106.91%
EPS Q/Q Growth		 -678.95% -32.73% 63.01% -148.15% 49.25% 70.59% 20.00% 18.75% - 66.67% -120.00%
Operating Cash Flow Q/Q Growth		 -14.40% -45.10% -52.57% 0.00% 29.55% -99.00% 13,375.78% -64.11% - -115.96% 537.93%
Free Cash Flow Firm Q/Q Growth		 1,605.42% 127.18% 42.20% 23.06% 9.15% -36.27% -57.85% -65.57% - 236.59% -66.31%
Invested Capital Q/Q Growth		 -4.04% -5.06% -7.39% -5.82% -6.65% 3.99% 1.79% -1.42% - -0.68% -0.02%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 0.00% 79.81% 77.24% 65.20% 22.40% 126.79% 141.67% 137.06% - 73.44% 71.59%
EBIT Margin		 0.00% 30.06% 12.05% -106.13% 6.18% -5.11% 6.21% -8.17% - 5.79% 6.93%
Profit (Net Income) Margin		 0.00% -538.26% -193.58% -669.76% -93.81% -109.28% -88.63% -73.67% - 27.88% -1.84%
Tax Burden Percent		 100.60% 101.27% 104.77% 101.14% 102.37% 108.69% 111.11% 116.33% - 11,616.49% -29.37%
Interest Burden Percent		 196.62% -1,768.51% -1,533.18% 623.98% -1,483.29% 1,967.01% -1,284.23% 774.79% - 4.15% 90.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -11,516.49% 129.37%
Return on Invested Capital (ROIC)		 0.00% 0.81% 0.25% -1.94% 0.27% -0.22% 0.26% -0.34% - 22.34% -0.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -8.05% -3.15% -9.29% -4.29% -1.38% -0.83% -1.10% - 14.34% -0.07%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -10.92% -4.26% -13.11% -6.50% -2.36% -1.42% -2.06% - 29.47% -0.14%
Return on Equity (ROE)		 0.00% -10.11% -4.00% -15.05% -6.23% -2.58% -1.17% -2.40% - 51.81% -0.21%
Cash Return on Invested Capital (CROIC)		 5.11% 10.08% 16.75% 21.21% 25.46% 16.22% 6.73% 2.72% - 0.34% 2.15%
Operating Return on Assets (OROA)		 0.00% 1.11% 0.35% -2.68% 0.38% -0.30% 0.35% -0.47% - 0.18% 0.23%
Return on Assets (ROA)		 0.00% -19.93% -5.60% -16.89% -5.73% -6.40% -5.01% -4.26% - 0.89% -0.06%
Return on Common Equity (ROCE)		 0.00% -10.11% -4.00% -15.04% -6.23% -2.58% -1.17% -2.40% - 51.80% -0.21%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -21.85% -28.14% -48.90% 0.00% -34.68% -29.58% -15.15% - -2.75% -0.65%
Net Operating Profit after Tax (NOPAT)		 -235 34 14 -89 19 -3.86 4.81 -6.02 - 798 -2.52
NOPAT Margin		 0.00% 21.04% 8.44% -74.29% 4.32% -3.58% 4.35% -5.72% - 672.42% -2.04%
Net Nonoperating Expense Percent (NNEP)		 4.22% 8.86% 3.40% 7.35% 4.56% 1.17% 1.08% 0.76% - 8.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 69.94% 87.95% 206.13% 93.82% 105.11% 93.79% 108.17% - 94.21% 93.07%
Earnings before Interest and Taxes (EBIT)		 -335 49 20 -127 27 -5.52 6.87 -8.59 - 6.87 8.60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -252 130 128 78 98 137 157 144 - 87 89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.35 0.38 0.38 0.60 0.49 0.76 0.53 0.65 - 0.61 0.61
Price to Tangible Book Value (P/TBV)		 0.35 0.00 0.31 0.48 0.49 0.00 0.00 0.00 - 0.61 0.44
Price to Revenue (P/Rev)		 3.07 3.69 4.64 7.59 2.38 3.85 2.87 3.49 - 5.86 5.69
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 19.71% 20.86% 15.16% 9.70% 11.65% 8.96% 7.56% 6.31% - 7.34% 7.58%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.71 0.74 0.72 0.83 0.80 0.87 0.81 0.86 - 0.85 0.85
Enterprise Value to Revenue (EV/Rev)		 14.33 18.13 21.76 28.31 10.94 13.19 13.18 14.07 - 25.42 24.85
Enterprise Value to EBITDA (EV/EBITDA)		 41.36 56.29 66.47 135.88 24.74 27.76 38.60 22.88 - 43.07 33.82
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 616.02 - 287.19 277.36
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 880.02 - 410.26 396.22
Enterprise Value to Operating Cash Flow (EV/OCF)		 24.70 27.91 27.63 40.17 44.36 72.22 0.00 56.25 - 55.65 53.23
Enterprise Value to Free Cash Flow (EV/FCFF)		 13.38 6.90 3.90 3.48 2.73 4.93 11.56 31.19 - 248.45 39.14
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.32 1.51 1.51 1.69 1.83 1.99 2.00 2.06 - 2.13 2.16
Long-Term Debt to Equity		 1.32 1.51 1.51 1.69 1.83 1.99 2.00 2.06 - 2.13 2.16
Financial Leverage		 1.25 1.36 1.35 1.41 1.52 1.71 1.72 1.86 - 2.06 2.07
Leverage Ratio		 2.34 2.44 2.44 2.49 2.61 2.80 2.84 2.99 - 3.18 3.20
Compound Leverage Factor		 4.60 -43.14 -37.41 15.57 -38.78 55.16 -36.51 23.13 - 0.13 2.90
Debt to Total Capital		 56.87% 60.10% 60.20% 62.88% 64.67% 66.53% 66.62% 67.35% - 68.01% 68.32%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 56.87% 60.10% 60.20% 62.88% 64.67% 66.53% 66.62% 67.35% - 68.01% 68.32%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.01% 0.01% 0.02% 0.02% 0.01% 0.01% 0.01% 0.01% - 0.01% 0.01%
Common Equity to Total Capital		 43.12% 39.89% 39.78% 37.11% 35.32% 33.46% 33.37% 32.64% - 31.99% 31.67%
Debt to EBITDA		 33.32 45.83 55.90 102.47 20.10 21.16 31.87 17.93 - 34.66 27.19
Net Debt to EBITDA		 32.50 44.81 52.28 99.40 19.35 19.66 30.19 17.19 - 33.14 26.08
Long-Term Debt to EBITDA		 33.32 45.83 55.90 102.47 20.10 21.16 31.87 17.93 - 34.66 27.19
Debt to NOPAT		 -43.58 -35.99 -70.74 -33.45 -408.04 -158.38 -140.08 689.87 - 330.19 318.51
Net Debt to NOPAT		 -42.50 -35.19 -66.16 -32.45 -392.71 -147.11 -132.68 661.42 - 315.66 305.50
Long-Term Debt to NOPAT		 -43.58 -35.99 -70.74 -33.45 -408.04 -158.38 -140.08 689.87 - 330.19 318.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.03% 0.03% 0.02% 0.03% 0.03% 0.04% 0.04% - 0.02% 0.02%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 930 2,113 3,004 3,697 4,035 2,572 1,084 373 - 817 275
Operating Cash Flow to CapEx		 401.63% 248.76% 232.03% 0.00% 471.83% 0.00% 0.00% 0.00% - -112.13% 835.82%
Free Cash Flow to Firm to Interest Expense		 0.00 19.44 29.62 34.80 0.00 22.21 8.36 2.82 - 6.13 2.04
Operating Cash Flow to Interest Expense		 0.00 0.68 0.35 0.00 0.00 0.01 0.80 0.28 - -0.11 0.46
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.41 0.20 0.00 0.00 0.01 0.80 0.28 - -0.20 0.41
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.04 0.03 0.03 0.06 0.06 0.06 0.06 - 0.03 0.03
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 17,698 16,803 15,562 14,657 13,682 14,227 14,483 14,278 - 14,208 14,205
Invested Capital Turnover		 0.05 0.04 0.03 0.03 0.06 0.06 0.06 0.06 - 0.03 0.03
Increase / (Decrease) in Invested Capital		 -1,165 -2,078 -2,990 -3,786 -4,016 -2,576 -1,079 -379 - -19 -278
Enterprise Value (EV)		 12,491 12,404 11,141 12,221 10,888 12,415 11,685 12,267 - 12,006 12,073
Market Capitalization		 2,675 2,527 2,375 3,278 2,372 3,622 2,545 3,046 - 2,767 2,763
Book Value per Share		 $12.74 $11.19 $10.32 $9.06 $8.05 $7.93 $8.04 $7.75 - $7.60 $7.52
Tangible Book Value per Share		 $12.74 ($7.84) $12.68 $11.43 $8.05 ($8.74) ($9.09) ($9.07) - $7.60 $10.44
Total Capital		 17,698 16,803 15,562 14,657 13,682 14,227 14,483 14,278 - 14,208 14,205
Total Debt		 10,064 10,099 9,369 9,216 8,848 9,465 9,649 9,616 - 9,663 9,705
Total Long-Term Debt		 10,064 10,099 9,369 9,216 8,848 9,465 9,649 9,616 - 9,663 9,705
Net Debt		 9,814 9,874 8,763 8,940 8,516 8,792 9,139 9,220 - 9,238 9,308
Capital Expenditures (CapEx)		 34 30 15 0.00 16 0.00 0.00 0.00 - 13 7.47
Net Nonoperating Expense (NNE)		 429 910 334 712 431 114 103 71 - 765 -0.24
Net Nonoperating Obligations (NNO)		 10,064 10,099 9,369 9,216 8,848 9,465 9,649 9,616 - 9,663 9,705
Total Depreciation and Amortization (D&A)		 84 81 108 205 71 142 150 153 - 80 80
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05 ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M 597.96M
Adjusted Diluted Earnings per Share		 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05 ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M 597.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 599.10M 600.10M 600.20M 600.40M 600.60M 600.80M 601.10M 601.50M 597.70M 598.10M 597.20M
Normalized Net Operating Profit after Tax (NOPAT)		 -235 34 14 -89 19 -3.86 4.81 -6.02 - 4.81 6.02
Normalized NOPAT Margin		 0.00% 21.04% 8.44% -74.29% 4.32% -3.58% 4.35% -5.72% - 4.05% 4.85%
Pre Tax Income Margin		 0.00% -531.53% -184.76% -662.21% -91.64% -100.54% -79.77% -63.33% - 0.24% 6.28%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.45 0.20 -1.19 0.00 -0.05 0.05 -0.06 - 0.05 0.06
NOPAT to Interest Expense		 0.00 0.31 0.14 -0.84 0.00 -0.03 0.04 -0.05 - 5.99 -0.02
EBIT Less CapEx to Interest Expense		 0.00 0.17 0.05 -1.19 0.00 -0.05 0.05 -0.06 - -0.04 0.01
NOPAT Less CapEx to Interest Expense		 0.00 0.04 -0.01 -0.84 0.00 -0.03 0.04 -0.05 - 5.89 -0.07
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -110.66% -36.30% -25.70% -13.69% -13.33% -19.66% 0.00% -47.86% - -122.01% -710.60%
Augmented Payout Ratio		 -110.66% -36.30% -25.70% -13.69% -13.33% -19.66% 0.00% -47.86% - -122.01% -812.43%

Financials Breakdown Chart

Key Financial Trends

Medical Properties Trust’s latest statements show a company that has made progress from the severe losses reported in 2024 and early 2025, but remains highly leveraged and dependent on noncash adjustments and asset-related activity. The second quarter of 2026 produced $124.0 million of revenue, up from $118.7 million in the first quarter and $110.7 million in the second quarter of 2025. However, revenue remains below the $165.1 million reported in the second quarter of 2024.

Profitability has improved substantially from the large impairment-driven losses of 2024. MPT reported a $2.6 million net loss attributable to common shareholders in Q2 2026, or $0.01 per share, compared with a $32.8 million profit in Q1 2026 and a $98.4 million loss in Q2 2025. The improvement from the prior year is encouraging, although the return to profitability remains inconsistent. Interest expense continues to rise, reaching $135.3 million in Q2 2026 versus $129.7 million in Q2 2025 and $101.4 million in Q2 2024.

Cash generation was mixed. Continuing operating activities generated $97.2 million in Q2 2026, but total operating cash flow was $62.4 million. That was a sharp improvement from the $14.3 million cash outflow in Q1 2026, but below the $103.5 million generated in Q2 2025. Depreciation, amortization and other noncash adjustments provided substantial support to operating cash flow, so reported net income does not fully capture the company’s underlying cash performance.

The balance sheet remains the primary concern for investors. At June 30, 2026, MPT held $396.6 million of cash against $9.7 billion of long-term debt. Total equity was $4.5 billion, down from $6.2 billion in Q2 2024 and $8.3 billion in Q2 2023. Retained earnings were negative $4.2 billion, reflecting the cumulative impact of prior losses and distributions. The data also contains restated and reclassified periods, including some records associated with an incorrect ticker in Q1 2023, so comparisons should be viewed as directional rather than perfectly like-for-like.

  • Profitability is recovering: The Q2 2026 common-shareholder loss of $2.6 million was far smaller than the $98.4 million loss in Q2 2025 and the $412.8 million loss in Q4 2024.
  • Revenue has stabilized recently: Quarterly revenue increased from $110.7 million in Q2 2025 to $124.0 million in Q2 2026, with Q2 also exceeding Q1 2026 revenue.
  • Operating cash flow rebounded sequentially: Total operating cash flow improved from a $14.3 million outflow in Q1 2026 to a $62.4 million inflow in Q2 2026.
  • Dividend payments have been reduced: The common dividend was $0.09 per share in Q1 and Q2 2026, below the $0.30 per share reported in Q2 2024 and $0.29 in Q2 2023, preserving more cash for balance-sheet needs.
  • Investment activity is changing: MPT spent $89.5 million purchasing investments in Q2 2026 and received $14.6 million from sales or maturities, resulting in an $82.3 million investing cash outflow. This may support future liquidity or portfolio repositioning, but the data does not show the expected returns.
  • Recent asset values are difficult to compare: Total assets were $14.7 billion in Q2 2026, but changes in the presentation of property, intangible and other assets make it difficult to isolate operating growth from reclassifications and valuation changes.
  • Leverage remains high: Long-term debt was $9.7 billion at the end of Q2 2026, more than twice reported common equity of $4.5 billion.
  • Interest costs are moving higher: Quarterly long-term debt interest expense increased from $101.4 million in Q2 2024 to $135.3 million in Q2 2026, placing continued pressure on earnings and cash flow.
  • Cash reserves have declined from earlier periods: Cash fell to $396.6 million in Q2 2026 from $606.6 million in Q2 2024, despite debt issuance and ongoing asset sales.
  • Dividend coverage remains a key risk: MPT paid $54.3 million in common dividends in Q2 2026 while reporting a common-shareholder loss and only $62.4 million of total operating cash flow. The reduced dividend is more manageable, but the margin of safety remains limited.
09/14/26 10:50 AM ETAI Generated. May Contain Errors.

Medical Properties Trust Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Medical Properties Trust's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Medical Properties Trust's net income appears to be on a downward trend, with a most recent value of -$275.94 million in 2025, falling from $139.93 million in 2015. The previous period was -$2.41 billion in 2024. Check out Medical Properties Trust's forecast to explore projected trends and price targets.

Over the last 10 years, Medical Properties Trust's total revenue changed from $441.88 million in 2015 to $461.66 million in 2025, a change of 4.5%.

Medical Properties Trust's total liabilities were at $10.39 billion at the end of 2025, a 9.9% increase from 2024, and a 196.8% increase since 2015.

In the past 10 years, Medical Properties Trust's cash and equivalents has ranged from $83.24 million in 2016 to $1.46 billion in 2019, and is currently $540.86 million as of their latest financial filing in 2025.


Related Companies

Financial statements for NYSE:MPT last updated on 8/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
Gold just passed our debt as the world's #1 asset
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
Print this before your next trade
Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...
Profits Run | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
What is Elon Building in Texas?
Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...
InvestorPlace | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel